HK drug firm seeks to list on Nasdaq
Print Edition
HONG Kong-based drugmaker Hutchison China MediTech Ltd has filed for an initial public offering in the United States, according to a regulatory filing.
The London-listed biopharmaceutical company, majority owned by Chinese conglomerate CK Hutchison Holdings Ltd, is also known as Chi-Med.
Far fewer Chinese companies have listed in the US so far this year than in 2014.
The US IPOs of two Chinese companies raised about US$150 million this year to June. In the corresponding period last year, the listing of 10 Chinese companies in the United States had raised over US$3.5 billion, according to Thomson Reuters data.
Hutchison China, founded in 2000 by Hutchison Whampoa Ltd, makes cancer and arthritis drugs and medical devices.
The company, which listed on the London Stock Exchange in 2006, has seven drug candidates in clinical-stage trials, three of which it is developing with units of AstraZeneca Plc, Eli Lilly & Co and Nestle SA.
Four of these drug candidates are for tumors and one each for lung cancer and rheumatoid arthritis.
Five of the seven drug candidates could be eligible for accelerated approval by the US Food and Drug Administration, Hutchison China said in a filing to the US Securities and Exchange Commission.
Hutchison China’s revenue more than doubled to US$87.3 million in 2014.
The firm plans to list on Nasdaq under the symbol “HCM.” It has set a target of up to US$100 million for the IPO, according to the filing.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
